Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview

被引:76
作者
Correia, Sonia [1 ,2 ]
Carvalho, Cristina [2 ]
Santos, Maria S. [1 ,2 ]
Seica, Raquel [3 ,4 ]
Oliveira, Catarina R. [1 ,5 ]
Moreira, Paula I. [1 ,3 ]
机构
[1] Univ Coimbra, Ctr Neurosci & Cell Biol, P-3000354 Coimbra, Portugal
[2] Univ Coimbra, Fac Sci & Technol, Dept Zool, P-300354 Coimbra, Portugal
[3] Univ Coimbra, Fac Med, Inst Physiol, P-300354 Coimbra, Portugal
[4] Univ Coimbra, Biomed Inst Res Light & Image, P-300354 Coimbra, Portugal
[5] Univ Coimbra, Fac Med, Inst Biochem, P-300354 Coimbra, Portugal
关键词
AMP-activated protein kinase; brain protection; diabetes-associated complications; hyperglycemia; insulin resistance; metformin; type; 2; diabetes; vasculoprotection;
D O I
10.2174/138955708786369546
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Type 2 diabetes is a major health problem associated with excess mortality and morbidity. Vascular complications are one of the most serious consequences of this disorder. Moreover, type 2 diabetes is also a risk factor for cerebral complications, including cognitive impairment and dementia. However, it has been shown that tight glycemic control contributes to reduce the incidence of diabetes-associated complications. Metformin is a potent antihyperglycemic agent widely used in the management of type 2 diabetes whose main actions are the suppression of gluconeogenesis and the improvement of glucose uptake and insulin sensitivity. This review is mainly devoted to describe the mechanisms of action underlying the antidiabetic effects of metformin. Furthermore, we will present evidence for the protective effects of metformin against diabetes-associated complications mainly cerebral and vascular complications. Finally, we will describe the few known side effects associated to this antidiabetic agent.
引用
收藏
页码:1343 / 1354
页数:12
相关论文
共 180 条
[91]   THE IMPACT OF METFORMIN THERAPY ON HEPATIC GLUCOSE-PRODUCTION AND SKELETAL-MUSCLE GLYCOGEN-SYNTHASE ACTIVITY IN OVERWEIGHT TYPE-II DIABETIC-PATIENTS [J].
JOHNSON, AB ;
WEBSTER, JM ;
SUM, CF ;
HESELTINE, L ;
ARGYRAKI, M ;
COOPER, BG ;
TAYLOR, R .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (09) :1217-1222
[92]   Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes [J].
Johnson, JA ;
Simpson, SH ;
Toth, EL ;
Majumdar, SR .
DIABETIC MEDICINE, 2005, 22 (04) :497-502
[93]   Contraindications to the use of metformin - Evidence suggests that it is time to amend the list [J].
Jones, GC ;
Macklin, JP ;
Alexander, WD .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7379) :4-5
[94]   Obesity, body fat distribution, insulin sensitivity and islet ß-cell function as explanations for metabolic diversity [J].
Kahn, SE ;
Prigeon, RL ;
Schwartz, RS ;
Fujimoto, WY ;
Knopp, RH ;
Brunzell, JD ;
Porte, D .
JOURNAL OF NUTRITION, 2001, 131 (02) :354S-360S
[95]   Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets [J].
Kakuma, T ;
Lee, Y ;
Higa, M ;
Wang, ZW ;
Pan, WT ;
Shimomura, I ;
Unger, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (15) :8536-8541
[96]   Metformin improves vascular function in insulin-resistant rats [J].
Katakam, PVG ;
Ujhelyi, MR ;
Hoenig, M ;
Miller, AW .
HYPERTENSION, 2000, 35 (01) :108-112
[97]   Roles of PPARs in health and disease [J].
Kersten, S ;
Desvergne, B ;
Wahli, W .
NATURE, 2000, 405 (6785) :421-424
[98]   The union of vascular and metabolic actions of insulin in sickness and in health [J].
Kim, JA ;
Koh, KK ;
Quon, MJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (05) :889-891
[99]   Metformin: An update [J].
Kirpichnikov, D ;
McFarlane, SI ;
Sowers, JR .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (01) :25-33
[100]   CELLULAR MECHANISM OF ACTION OF METFORMIN [J].
KLIP, A ;
LEITER, LA .
DIABETES CARE, 1990, 13 (06) :696-704